Mašić, Dženan http://orcid.org/0000-0001-7265-9160
Stengaard-Pedersen, Kristian http://orcid.org/0000-0001-7991-2456
Løgstrup, Brian Bridal http://orcid.org/0000-0002-4218-0033
Hørslev-Petersen, Kim http://orcid.org/0000-0002-5475-7610
Hetland, Merete Lund http://orcid.org/0000-0003-4229-6818
Junker, Peter http://orcid.org/0000-0002-2684-9964
Østergaard, Mikkel http://orcid.org/0000-0003-3690-467X
Ammitzbøll, Christian http://orcid.org/0000-0002-8535-1613
Möller, Sören http://orcid.org/0000-0003-0858-4269
Christensen, Robin http://orcid.org/0000-0002-6600-0631
Ellingsen, Torkell http://orcid.org/0000-0003-0426-4962
Funding for this research was provided by:
Gigtforeningen (R142-A4110)
Gigtforeningen (R135-A3684)
Syddansk Universitet
Odense Universitetshospital
Article History
Received: 18 August 2020
Accepted: 16 November 2020
First Online: 2 January 2021
Compliance with ethical standards
:
: Dr. Masic has nothing to disclose. Dr. Stengaard-Pedersen has nothing to disclose. Dr. Løgstrup has nothing to disclose. Dr. Hørslev-Petersen has nothing to disclose. Dr. Hetland reports grants from Bristol-Myers Squibb, grants from AbbVie, grants from Roche, grants from Novartis, grants and personal fees from Merck, grants and personal fees from Biogen, grants and personal fees from Pfizer, personal fees from Eli Lilly, personal fees from Orion Pharma, personal fees from CellTrion, personal fees from Samsung Bioepsi, personal fees from Janssen Biologics B.V, personal fees from Diakonhjemmet Sykehus, personal fees from MSD, outside the submitted work; and I chair the sterring committee of the Danish Rheumatology Quality Registry (DANBIO), which receives public funding from the hospital owners and funding from pharmaceutical companies. I co-chair EuroSpA, which generates real-world evidence of treatment of psoriatic arthritis and axial spondyloarthritis based on secondary data, and is partly funded by Novartis. Dr. Junker has nothing to disclose. Dr. Østergaard reports grants, personal fees and non-financial support from AbbVie, grants, personal fees and non-financial support from BMS, personal fees from Boehringer-Ingelheim, personal fees from Eli Lilly, personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Merck, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from UCB, grants and personal fees from Celgene, personal fees from Sanofi, personal fees from Regeneron, grants, personal fees and non-financial support from Novartis, personal fees from Orion, personal fees from Hospira, outside the submitted work. Dr. Ammitzbøll has nothing to disclose. Dr. Möller has nothing to disclose. Dr. Christensen reports other from Lecture: Research Methods (Pfizer, DK; 2017), other from Lecture: GRADE Lecture (Celgene, DK; 2017), other from Ad Board Lecture: CAM (Orkla Health, DK; 2017), other from Project Grant: "GreenWhistle" (Mundipharma, 2019), other from Lecture: Diet in RMD (Novartis, DK; 2019), other from Consultancy Report: Network MA’s (Biogen, DK; 2017), other from Ad Board Lecture: GRADE (Lilly, DK; 2017), other from Consultancy Report: GRADE (Celgene, 2018), other from Lecture: Network MA's (LEO; 2020), outside the submitted work; and Musculoskeletal Statistics Unit, The Parker Institute is grateful for the financial support received from public and private foundations, companies and private individuals over the years. The Parker Institute is supported by a core grant from the Oak Foundation; The Oak Foundation is a group of philanthropic organizations that, since its establishment in 1983, has given grants to not-for-profit organizations around the world. Dr. Ellingsen has nothing to disclose.
: The study was approved by the Danish Data Protection Agency (2019-522-0133) and the Ethics Committee of the Central Denmark Region (1-10-72-436-17).